Skip to main content
UniHealth

Doctor search

Chitra Venkatasubramanian, MD

Neurology · Stanford

NPI 1912930678

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Venkatasubramanian’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A84449 · Current

Licensed to practise in California · since 2003 · expires 2027-08-31 · Dr. M. G. R. University, Coimbatore Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$56,581

Medicare paid this office $56,581 for 143 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Critical care, first 30-74 minutes110$45,983$185
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$3,298$106
Long return visit (40+ min)18$2,383$125
New patient visit (60+ min)12$1,954$163

Who their Medicare patients are

143 Original Medicare patients in 2024. Average age 74 · Under 65 11% · 85 and older 14% · Women 46% · Also on Medicaid 32% · Health risk score 2.22. Above the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 75% · Stroke 74% · Diabetes 45% · Coronary heart disease 45% · Chronic kidney disease 41% · Atrial fibrillation 41% · Heart failure 33% · Depression 29% · Dementia 29% · COPD 21% · Cancer 16%.

The office billed $499,352, Medicare allowed $72,046 and paid $56,581; for 342 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024143342742.22$499,352$56,581
2023154379742.51$614,376$68,003
2022147375722.84$629,231$68,752
2021133325732.12$539,023$60,988
2020164367722.22$567,775$70,567
2019110241742.34$323,277$43,372
2018149388752.05$550,304$71,744
2017131310732.31$438,058$56,670
2016141315741.98$449,970$57,815
2015147426721.80$881,043$78,055
2014129326741.70$354,865$57,441
2013137333741.97$355,507$57,487

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Critical care, first 30-74 minutes120$60,234$191
Long return visit (40+ min)21$3,296$127
New patient visit (60+ min)12$1,882$157

2022: 2 services

Original Medicare services billed in 2022
Critical care, first 30-74 minutes125$63,227$195
Critical care, each additional 30 minutes11$1,468$98

2021: 2 services

Original Medicare services billed in 2021
Critical care, first 30-74 minutes115$55,397$199
Long return visit (40+ min)12$2,199$129

2020: 2 services

Original Medicare services billed in 2020
Critical care, first 30-74 minutes145$66,283$201
Long return visit (40+ min)11$1,150$105

2019: 3 services

Original Medicare services billed in 2019
Critical care, first 30-74 minutes92$38,916$198
Critical care, each additional 30 minutes13$2,085$99
Long return visit (40+ min)13$1,312$94

2018: 2 services

Original Medicare services billed in 2018
Critical care, first 30-74 minutes131$66,965$195
Critical care, each additional 30 minutes11$1,570$98

2017: 2 services

Original Medicare services billed in 2017
Critical care, first 30-74 minutes120$52,711$195
Critical care, each additional 30 minutes14$2,164$98

2016: 2 services

Original Medicare services billed in 2016
Critical care, first 30-74 minutes121$53,986$193
New patient visit (60+ min)14$1,706$122

2015: 3 services

Original Medicare services billed in 2015
Critical care, first 30-74 minutes118$71,361$196
Long return visit (40+ min)16$1,973$99
Critical care, each additional 30 minutes14$1,867$98

2014: 4 services

Original Medicare services billed in 2014
Critical care, first 30-74 minutes101$49,063$195
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$2,588$92
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,158$180
Long return visit (40+ min)12$1,384$92

2013: 4 services

Original Medicare services billed in 2013
Critical care, first 30-74 minutes100$50,433$190
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,093$174
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$1,613$90
Long return visit (40+ min)11$1,053$81

Medicaid work

$22,214 in 2024

Medicaid paid $22,214 for 111 billed services this clinician did in 2024, up to 23 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes111$22,214
Medicaid work by year
2024111123$22,214
2023244128$24,370
2022188116$24,669
2021197118$21,088
2020194123$20,539
201925113$2,294
2018103115$7,755
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes244$24,370

2022

Largest Medicaid services in 2022
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes188$24,669

2021

Largest Medicaid services in 2021
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes197$21,088

2020

Largest Medicaid services in 2020
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes194$20,539

2019

Largest Medicaid services in 2019
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes25$2,294

2018

Largest Medicaid services in 2018
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes103$7,755

Money from drug and device companies

$61,506 in 2025

Industry payments by year
2025326$59,815$61,506
2024643$84,804$88,731
2023324$28,700$31,933
2022333$23,338$25,902
2021117$17,325$17,325
202027$23,869$23,869
2019319$9,625$10,793

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
CeribellPocket Eeg Device$60,090
21 payments
  • Consulting for Pocket Eeg Device · 2025-11-01 · $2,778
  • Consulting for Pocket Eeg Device · 2025-11-01 · $7,160
  • Travel for Pocket Eeg Device · 2025-11-01 · $283
  • Consulting for Pocket Eeg Device · 2025-11-01 · $6,100
  • Meals for Pocket Eeg Device · 2025-10-27 · $140
  • Meals for Pocket Eeg Device · 2025-09-18 · $86
  • Consulting for Pocket Eeg Device · 2025-09-15 · $13,840
  • Travel for Pocket Eeg Device · 2025-09-15 · $108
  • Consulting for Pocket Eeg Device · 2025-09-15 · $3,138
  • Consulting for Pocket Eeg Device · 2025-08-15 · $2,800
  • Consulting for Pocket Eeg Device · 2025-08-15 · $5,500
  • Consulting for Pocket Eeg Device · 2025-08-15 · $5,600
  • Travel for Pocket Eeg Device · 2025-08-15 · $538
  • Consulting for Pocket Eeg Device · 2025-06-01 · $4,000
  • Meals for Pocket Eeg Device · 2025-05-22 · $74
  • Consulting for Pocket Eeg Device · 2025-05-01 · $3,600
  • Meals for Pocket Eeg Device · 2025-03-16 · $25
  • Meals for Pocket Eeg Device · 2025-03-16 · $149
  • Consulting for Pocket Eeg Device · 2025-01-02 · $3,200
  • Travel for Pocket Eeg Device · 2025-01-02 · $171
  • Consulting for Pocket Eeg Device · 2025-01-01 · $800
AbbvieSkyrizi$1,300
3 payments
  • Consulting for Skyrizi · 2025-05-30 · $650
  • Consulting for Skyrizi · 2025-04-08 · $325
  • Consulting for Skyrizi · 2025-04-07 · $325
United TherapeuticsTyvaso$116
2 payments
  • Meals for Tyvaso · 2025-10-28 · $56
  • Meals for Tyvaso · 2025-10-08 · $60
See all 26 published payments
Every published payment
CeribellConsulting · 2025-11-01Pocket Eeg Device$2,778
CeribellConsulting · 2025-11-01Pocket Eeg Device$7,160
CeribellTravel · 2025-11-01Pocket Eeg Device$283
CeribellConsulting · 2025-11-01Pocket Eeg Device$6,100
United TherapeuticsMeals · 2025-10-28Tyvaso$56
CeribellMeals · 2025-10-27Pocket Eeg Device$140
United TherapeuticsMeals · 2025-10-08Tyvaso$60
CeribellMeals · 2025-09-18Pocket Eeg Device$86
CeribellConsulting · 2025-09-15Pocket Eeg Device$13,840
CeribellTravel · 2025-09-15Pocket Eeg Device$108
CeribellConsulting · 2025-09-15Pocket Eeg Device$3,138
CeribellConsulting · 2025-08-15Pocket Eeg Device$2,800
CeribellConsulting · 2025-08-15Pocket Eeg Device$5,500
CeribellConsulting · 2025-08-15Pocket Eeg Device$5,600
CeribellTravel · 2025-08-15Pocket Eeg Device$538
CeribellConsulting · 2025-06-01Pocket Eeg Device$4,000
AbbvieConsulting · 2025-05-30Skyrizi$650
CeribellMeals · 2025-05-22Pocket Eeg Device$74
CeribellConsulting · 2025-05-01Pocket Eeg Device$3,600
AbbvieConsulting · 2025-04-08Skyrizi$325
AbbvieConsulting · 2025-04-07Skyrizi$325
CeribellMeals · 2025-03-16Pocket Eeg Device$25
CeribellMeals · 2025-03-16Pocket Eeg Device$149
CeribellConsulting · 2025-01-02Pocket Eeg Device$3,200
CeribellTravel · 2025-01-02Pocket Eeg Device$171
CeribellConsulting · 2025-01-01Pocket Eeg Device$800
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $88,731

Payments by company in 2024
CeribellPocket Eeg Device$67,337
8 payments
  • Meals for Pocket Eeg Device · 2024-12-06 · $121
  • Consulting for Pocket Eeg Device · 2024-11-01 · $6,200
  • Consulting for Pocket Eeg Device · 2024-11-01 · $20,008
  • Consulting for Pocket Eeg Device · 2024-09-20 · $7,527
  • Consulting for Pocket Eeg Device · 2024-09-12 · $2,800
  • Consulting for Pocket Eeg Device · 2024-09-01 · $10,876
  • Consulting for Pocket Eeg Device · 2024-09-01 · $14,400
  • Consulting for Pocket Eeg Device · 2024-03-01 · $5,406
AbbvieSkyrizi$14,588
13 payments
  • Consulting for Skyrizi · 2024-12-11 · $650
  • Consulting for Skyrizi · 2024-11-21 · $1,300
  • Consulting for Skyrizi · 2024-11-05 · $2,600
  • Consulting for Rinvoq · 2024-10-16 · $975
  • Consulting for Skyrizi · 2024-10-16 · $650
  • Consulting · 2024-09-11 · $938
  • Consulting for Rinvoq · 2024-07-23 · $650
  • Consulting · 2024-07-17 · $650
  • Consulting for Rinvoq · 2024-06-26 · $1,625
  • Consulting for Skyrizi · 2024-05-16 · $650
  • Consulting for Rinvoq · 2024-03-26 · $1,625
  • Consulting for Rinvoq · 2024-02-12 · $975
  • Consulting for Skyrizi · 2024-02-12 · $1,300
AstraZeneca Pharmaceuticals LPAndexxa$3,326
5 payments
  • Education for Andexxa · 2024-09-11 · $27
  • Travel · 2024-01-12 · $8
  • Meals · 2024-01-12 · $111
  • Consulting · 2024-01-12 · $3,000
  • Travel · 2024-01-12 · $181
Alnylam PharmaceuticalsNone$3,182
14 payments
  • Meals · 2024-05-10 · $21
  • Travel · 2024-05-10 · $27
  • Travel · 2024-05-09 · $219
  • Travel · 2024-05-09 · $101
  • Meals · 2024-05-09 · $24
  • Meals · 2024-05-09 · $35
  • Meals · 2024-05-09 · $131
  • Meals · 2024-05-09 · $49
  • Travel · 2024-05-09 · $101
  • Meals · 2024-05-09 · $24
  • Meals · 2024-05-09 · $26
  • Travel · 2024-05-09 · $28
  • Meals · 2024-05-09 · $4
  • Travel · 2024-05-08 · $2,393
UcbBriviact$196
2 payments
  • Meals for Briviact · 2024-10-16 · $71
  • Meals for Briviact · 2024-08-16 · $125
Hyperfine OperationsSwoop$102
1 payment
  • Meals for Swoop · 2024-02-15 · $102

2023: $31,933

Payments by company in 2023
AbbVieSkyrizi$27,200
16 payments
  • Consulting for Rinvoq · 2023-11-21 · $650
  • Consulting for Rinvoq · 2023-11-16 · $2,275
  • Consulting for Skyrizi · 2023-11-02 · $1,300
  • Consulting for Rinvoq · 2023-10-24 · $2,600
  • Consulting for Skyrizi · 2023-09-19 · $1,625
  • Consulting for Skyrizi · 2023-09-13 · $3,250
  • Consulting for Rinvoq · 2023-08-03 · $975
  • Consulting for Rinvoq · 2023-07-13 · $650
  • Consulting for Skyrizi · 2023-06-26 · $1,300
  • Consulting for Rinvoq · 2023-06-08 · $650
  • Consulting for Rinvoq · 2023-04-11 · $1,300
  • Consulting for Skyrizi · 2023-04-11 · $6,175
  • Consulting for Rinvoq · 2023-03-28 · $975
  • Consulting for Rinvoq · 2023-03-10 · $2,275
  • Consulting · 2023-02-23 · $550
  • Consulting for Rinvoq · 2023-02-13 · $650
AstraZeneca Pharmaceuticals LPAndexxa$3,087
5 payments
  • Travel for Andexxa · 2023-10-11 · $363
  • Travel for Andexxa · 2023-10-11 · $234
  • Meals for Andexxa · 2023-10-11 · $117
  • Travel for Andexxa · 2023-10-11 · $2,166
  • Travel for Andexxa · 2023-10-11 · $207
CeribellCeribell Rapid Response Eeg$1,646
2 payments
  • Meals for Ceribell Rapid Response Eeg · 2023-08-10 · $146
  • Consulting for Ceribell Rapid Response Eeg · 2023-04-01 · $1,500

2022: $25,902

Payments by company in 2022
AbbvieRinvoq$23,338
17 payments
  • Consulting · 2022-12-12 · $1,100
  • Consulting for Rinvoq · 2022-11-21 · $1,950
  • Consulting · 2022-09-30 · $1,650
  • Consulting · 2022-09-20 · $975
  • Consulting · 2022-08-12 · $1,650
  • Consulting · 2022-08-12 · $1,100
  • Consulting for Rinvoq · 2022-07-13 · $325
  • Consulting for Rinvoq · 2022-07-11 · $650
  • Consulting for Rinvoq · 2022-06-09 · $2,925
  • Consulting · 2022-06-09 · $3,300
  • Consulting for Rinvoq · 2022-05-19 · $413
  • Consulting for Rinvoq · 2022-05-19 · $975
  • Consulting for Rinvoq · 2022-04-13 · $550
  • Consulting for Rinvoq · 2022-04-12 · $1,925
  • Consulting for Rinvoq · 2022-04-12 · $1,100
  • Consulting · 2022-04-04 · $1,925
  • Consulting for Rinvoq · 2022-01-13 · $825
BiogenNone$2,418
15 payments
  • Meals · 2022-10-20 · $27
  • Meals · 2022-10-05 · $81
  • Meals · 2022-10-05 · $61
  • Travel · 2022-10-05 · $24
  • Meals · 2022-10-05 · $32
  • Travel · 2022-10-05 · $80
  • Meals · 2022-10-05 · $32
  • Meals · 2022-10-04 · $30
  • Meals · 2022-10-04 · $14
  • Meals · 2022-10-04 · $14
  • Travel · 2022-10-04 · $80
  • Travel · 2022-10-04 · $80
  • Travel · 2022-10-04 · $226
  • Meals · 2022-10-04 · $129
  • Travel · 2022-09-30 · $1,507
UcbBriviact$146
1 payment
  • Meals for Briviact · 2022-10-18 · $146

2021: $17,325

Payments by company in 2021
AbbVieNone$17,325
17 payments
  • Consulting · 2021-12-07 · $1,650
  • Consulting · 2021-12-07 · $550
  • Consulting · 2021-12-06 · $1,650
  • Consulting · 2021-11-04 · $825
  • Consulting · 2021-10-08 · $1,650
  • Consulting · 2021-10-04 · $550
  • Consulting · 2021-09-07 · $275
  • Consulting · 2021-08-18 · $550
  • Consulting · 2021-08-10 · $1,100
  • Consulting · 2021-07-12 · $2,200
  • Consulting · 2021-07-12 · $1,375
  • Consulting · 2021-06-10 · $550
  • Consulting · 2021-06-08 · $275
  • Consulting · 2021-06-07 · $1,650
  • Consulting · 2021-06-07 · $550
  • Consulting · 2021-05-07 · $550
  • Consulting · 2021-02-05 · $1,375

2020: $23,869

Payments by company in 2020
AbbVieNone$16,269
6 payments
  • Consulting · 2020-10-06 · $550
  • Consulting · 2020-09-02 · $1,557
  • Consulting · 2020-08-03 · $3,300
  • Consulting · 2020-06-03 · $4,813
  • Consulting · 2020-06-01 · $1,100
  • Consulting · 2020-06-01 · $4,950
Portola PharmaceuticalsAndexxa$7,600
1 payment
  • Paid to speak or teach for Andexxa · 2020-07-31 · $7,600

2019: $10,793

Payments by company in 2019
AbbVieNone$10,711
17 payments
  • Consulting · 2019-10-29 · $550
  • Travel · 2019-10-21 · $659
  • Meals · 2019-10-21 · $15
  • Meals · 2019-10-21 · $27
  • Meals · 2019-10-21 · $40
  • Consulting · 2019-10-21 · $3,575
  • Meals · 2019-10-21 · $17
  • Meals · 2019-10-21 · $8
  • Travel · 2019-10-21 · $49
  • Travel · 2019-10-20 · $217
  • Meals · 2019-10-20 · $9
  • Meals · 2019-10-20 · $26
  • Travel · 2019-10-20 · $19
  • Consulting · 2019-09-27 · $1,650
  • Consulting · 2019-07-30 · $550
  • Consulting · 2019-04-04 · $1,650
  • Consulting · 2019-03-26 · $1,650
MedivanceArctic Sun$57
1 payment
  • Meals for Arctic Sun · 2019-08-17 · $57
CeribellNone$24
1 payment
  • Meals · 2019-10-17 · $24

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · A Phase II, Patient and Investigator-Blinded, Randomized, Placebo-Controlled Study To Evaluate Efficacy, Safety and Tolerability of Baf312 in Patients With Stroke Due To Intracerebral Hemorrhage (Ich) · 2019Their institution$129,300
Alnylam Pharmaceuticals Inc. · A Phase 2 Trial of Aln-App in Patients With Cerebral Amyloid Angiopathy (Cappricorn-1) · 2025Their institution$110,166
Biogen, Inc. · Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2021Their institution$70,509
Biogen, Inc. · Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2020Their institution$58,266
C. R. BARD, INC. & SUBSIDIARIES · Intrepid Bmd1111 · 2019Their institution$43,936
Novartis Pharmaceuticals Corporation · A Phase II, Patient and Investigator-Blinded, Randomized, Placebo-Controlled Study To Evaluate Efficacy, Safety and Tolerability of Baf312 in Patients With Stroke Due To Intracerebral Hemorrhage (Ich) · 2020Their institution$35,845
Biogen, Inc. · Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2022Their institution$33,753
C. R. Bard, Inc. & Subsidiaries · Intrepid Bmd1111 · 2020Their institution$30,272
Biogen, Inc. · Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2019Their institution$26,841
C. R. Bard, Inc. & Subsidiaries · Intrepid Bmd1111 · 2021Their institution$25,216
Biogen, Inc. · Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2023Their institution$13,775
ABBVIE INC. · A Study To Evaluate the Long-Term Efficacy Safety and Tolerability of Repeated Administration of Upadacitinib (Abt-494) in Participants With Crohn Disease · 2025This clinician$8,625
Novartis Pharmaceuticals Corporation · A Phase II, Patient and Investigator-Blinded, Randomized, Placebo-Controlled Study To Evaluate Efficacy, Safety and Tolerability of Baf312 in Patients With Stroke Due To Intracerebral Hemorrhage (Ich) · 2021Their institution$4,256
C. R. Bard, Inc. & Subsidiaries · Intrepid Bmd1111 · 2022Their institution$3,744
ABBVIE INC. · A Study Comparing Risankizumab To Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have A History of Inadequate Response Or Intolerance To Biologic Therapy(Ies) · 2025This clinician$1,500
Biogen, Inc. · Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2024Their institution$1,468

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1912930678
Licence
CA A84449California A84449: Current · expires 2027-08-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 2084V0102X (2084V0102X); Federal specialty code 2084A2900X (2084A2900X); Neurology (2084N0400X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-07-08
NPI last updated
2023-07-06
NPI record certified
2023-07-06

This is when the NPI record was last certified, not a medical board exam.